Rigel Pharmaceuticals (RIGL) Long-Term Debt Issuances (2022 - 2023)
Rigel Pharmaceuticals' quarterly Long-Term Debt Issuances came in at $20.0 million in Q1 2023, up 100.0% year-on-year from $10.0 million in Q1 2022, and up 107.81% quarter-over-quarter from $9.6 million in Q3 2022.
Rigel Pharmaceuticals has reported Long-Term Debt Issuances for 2 years, with the latest figure at $20.0 million in Q1 2023.
- For the quarter ending Q1 2023, Long-Term Debt Issuances rose 100.0% year-over-year to $20.0 million; the trailing twelve-month figure through Dec 2023 stood at $20.0 million (up 2.09% YoY), and the FY2023 full-year result was $20.0 million, up 2.09% from the prior year.
- Long-Term Debt Issuances for Q1 2023 stood at $20.0 million, up from $9.6 million in the prior quarter.
- The five-year high for Long-Term Debt Issuances was $20.0 million in Q1 2023, with the low at -$33000.0 in Q2 2022.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 2.73 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Rigel Pharmaceuticals | 551.62 Mn | 404.94 Mn | 54.21 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2023 | 19.95 Mn |
| Mar 31, 2023 | 19.95 Mn |
| Sep 30, 2022 | 9.60 Mn |
| Sep 30, 2022 | 9.60 Mn |
| Jun 30, 2022 | -33,000.00 |
| Jun 30, 2022 | -33,000.00 |
| Mar 31, 2022 | 9.98 Mn |
| Mar 31, 2022 | 9.98 Mn |